Evidence map›Paper›PMID 37302039›Full record

Observational studyJournal of Parkinson's disease2023

Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results.

K Ray Chaudhuri, Norbert Kovács, Francesco E Pontieri, Jason Aldred, Paul Bourgeois, Thomas L Davis, Esther Cubo, Marieta Anca-Herschkovitsch, Robert Iansek, Mustafa S Siddiqui and 7 more

Registry-linked trialOpen access · diamondAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of Parkinson's disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02611713 (DUOdopa/Duopa in Patients With Advanced Parkinson's Disease), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02611713 completednot on this map

DUOdopa/Duopa in Patients With Advanced Parkinson's Disease (PD) - a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)

TypeobservationalSponsorAbbVieRan2016 to 2020Enrolled213ConditionsAdvanced Parkinson's Disease
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Effects of levodopa/carbidopa intestinal gel infusion on autonomic symptoms in advanced Parkinson's disease: a systematic review.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025
    Pooled it
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Review
  7. Advanced Therapeutics in Parkinson's Disease: What's New?Current neurology and neuroscience reports · 2026
    Review
  8. Sleep quality improvement after switching from levodopa/carbidopa intestinal gel to continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced Parkinson's disease: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  9. Review
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 9 countries.

K Ray ChaudhuriParkinson's Foundation International Centre of Excellence, King's College Hospital, and King's College Institute of Psychiatry, Biomedical Research Centre, Psychology & Neuroscience, London, United Kingdom.
Norbert KovácsDepartment of Neurology, University of Pécs, Pécs, Hungary.
Francesco E PontieriDepartment of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Jason AldredSelkirk Neurology, Spokane, WA, USA.
Paul BourgeoisDepartment of Neurology AZ Groeninge, Kortrijk, Belgium.
Thomas L DavisDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
Esther CuboNeurology Department, Hospital Universitario Burgos, Burgos, Spain.
Marieta Anca-HerschkovitschDepartment of Neurology, Edith Wolfson Medical Center, Holon, Israel.
Robert IansekKingston Centre, Monash Health, Melbourne, Victoria, Australia.
Mustafa S SiddiquiDepartment of Neurology, Wake Forest School of Medicine, Winston Salem, NC, USA.
Mihaela SimuDepartment of Neurology, Victor Babes Universityof Medicine and Pharmacy, Timisoara, Romania.
Lars BergmannAbbVie Inc., North Chicago, IL, USA.
Mayra BallinaAbbVie Inc., North Chicago, IL, USA.
Pavnit KukrejaAbbVie Inc., North Chicago, IL, USA.
Omar LadhaniAbbVie Inc., North Chicago, IL, USA.
Jia JiaAbbVie Inc., North Chicago, IL, USA.
David G StandaertDepartment of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
AbbVie (United States) · USAZ Groeninge · BEFondazione Santa Lucia · ITHospital Universitario de Burgos · ESKing's College Hospital NHS Foundation Trust · GBMonash Health · AUNeurology, Inc · USUniversity of Alabama at Birmingham · USUniversity of Pecs · HUVanderbilt University Medical Center · USVictor Babeș University of Medicine and Pharmacy Timișoara · ROWake Forest University · USWolfson Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLevodopa-carbidopa intestinal gel (LCIG) improves motor and non-motor symptoms in patients with advanced Parkinson's disease (aPD).

objectiveTo present the final 36-month efficacy and safety results from DUOGLOBE (DUOdopa/Duopa in Patients with Advanced Parkinson's Disease - a GLobal OBservational Study Evaluating Long-Term Effectiveness; NCT02611713).

methodsDUOGLOBE was an international, prospective, long-term, real-world, observational study of patients with aPD initiating LCIG in routine clinical care. The primary endpoint was change in patient-reported "Off" time to Month 36. Safety was assessed by monitoring serious adverse events (SAEs).

resultsSignificant improvements in "Off" time were maintained over 3 years (mean [SD]: -3.3 hours [3.7]; p < 0.001). There were significant improvements to Month 36 in total scores of the Unified Dyskinesia Rating Scale (-5.9 [23.7]; p = 0.044), Non-Motor Symptoms Scale (-14.3 [40.5]; p = 0.002), Parkinson's Disease Sleep Scale-2 (-5.8 [12.9]; p < 0.001), and Epworth Sleepiness Scale (-1.8 [6.0]; p = 0.008). Health-related quality of life and caregiver burden significantly improved through Months 24 and 30, respectively (Month 24, 8-item Parkinson's Disease Questionnaire Summary Index, -6.0 [22.5]; p = 0.006; Month 30, Modified Caregiver Strain Index, -2.3 [7.6]; p = 0.026). Safety was consistent with the well-established LCIG profile (SAEs: 54.9% of patients; discontinuations: 54.4%; discontinuations due to an adverse event: 27.2%). Of 106 study discontinuations, 32 patients (30.2%) continued LCIG outside the study.

conclusionDUOGLOBE demonstrates real-world, long-term, reductions in motor and non-motor symptoms in patients with aPD treated with LCIG.

Indexed as

LevodopaParkinson DiseaseAntiparkinson AgentsCarbidopaDrug CombinationsGelsHumansProspective StudiesQuality of LifeAntiparkinson AgentsCarbidopacarbidopa, levodopa drug combinationDrug CombinationsGelsLevodopaDUOGLOBEdyskinesialevodopa-carbidopa intestinal gelParkinson’s diseasereal-world data

Identifiers

PMID37302039
PMCPMC10473130
OpenAlexW4379519511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.